LU85839A1 - Perfectionnements a la therapie par l'interleukine - Google Patents

Perfectionnements a la therapie par l'interleukine Download PDF

Info

Publication number: LU85839A1
Authority: LU; Luxembourg
Prior art keywords: liposomes; interleukin; solution; mixture; lipid
Prior art date: 1984-04-09

Application number

LU85839A

Other languages

English (en)

French (fr)

Original Assignee

Sandoz Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-04-09

Filing date

1985-04-05

Publication date

1985-12-16

1984-04-09 Priority claimed from GB848409125A external-priority patent/GB8409125D0/en

1984-04-09 Priority claimed from GB848409128A external-priority patent/GB8409128D0/en

1984-04-09 Priority claimed from GB848409127A external-priority patent/GB8409127D0/en

1984-04-09 Priority claimed from GB848409126A external-priority patent/GB8409126D0/en

1984-08-10 Priority claimed from GB848420381A external-priority patent/GB8420381D0/en

1984-09-19 Priority claimed from GB848423700A external-priority patent/GB8423700D0/en

1984-09-19 Priority claimed from GB848423701A external-priority patent/GB8423701D0/en

1985-04-05 Application filed by Sandoz Sa filed Critical Sandoz Sa

1985-12-16 Publication of LU85839A1 publication Critical patent/LU85839A1/fr

Links

102000015696 Interleukins Human genes 0.000 title claims description 75
108010063738 Interleukins Proteins 0.000 title claims description 75
238000002560 therapeutic procedure Methods 0.000 title description 3
239000002502 liposome Substances 0.000 claims description 139
108010002350 Interleukin-2 Proteins 0.000 claims description 55
150000002632 lipids Chemical class 0.000 claims description 41
239000000243 solution Substances 0.000 claims description 38
239000000203 mixture Substances 0.000 claims description 37
238000000034 method Methods 0.000 claims description 36
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 25
239000000725 suspension Substances 0.000 claims description 23
239000002904 solvent Substances 0.000 claims description 22
239000003960 organic solvent Substances 0.000 claims description 19
238000011282 treatment Methods 0.000 claims description 18
238000002604 ultrasonography Methods 0.000 claims description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
238000002156 mixing Methods 0.000 claims description 11
230000008569 process Effects 0.000 claims description 11
239000000872 buffer Substances 0.000 claims description 10
238000001704 evaporation Methods 0.000 claims description 10
230000008020 evaporation Effects 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 7
239000007853 buffer solution Substances 0.000 claims description 6
239000007864 aqueous solution Substances 0.000 claims description 4
238000006243 chemical reaction Methods 0.000 claims description 4
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
102000000588 Interleukin-2 Human genes 0.000 description 47
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
239000000787 lecithin Substances 0.000 description 24
235000010445 lecithin Nutrition 0.000 description 24
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 22
229940067606 lecithin Drugs 0.000 description 22
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 20
238000012360 testing method Methods 0.000 description 20
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
230000000694 effects Effects 0.000 description 17
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
238000005119 centrifugation Methods 0.000 description 16
210000004027 cell Anatomy 0.000 description 15
238000002360 preparation method Methods 0.000 description 15
210000001744 T-lymphocyte Anatomy 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
239000012071 phase Substances 0.000 description 11
239000008363 phosphate buffer Substances 0.000 description 11
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
239000000839 emulsion Substances 0.000 description 9
235000001014 amino acid Nutrition 0.000 description 8
150000001413 amino acids Chemical class 0.000 description 8
239000008346 aqueous phase Substances 0.000 description 8
230000012010 growth Effects 0.000 description 8
239000007788 liquid Substances 0.000 description 8
239000006228 supernatant Substances 0.000 description 8
238000010348 incorporation Methods 0.000 description 7
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
239000000499 gel Substances 0.000 description 6
229910052751 metal Inorganic materials 0.000 description 6
239000002184 metal Substances 0.000 description 6
230000035755 proliferation Effects 0.000 description 6
229920006395 saturated elastomer Polymers 0.000 description 6
210000000952 spleen Anatomy 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 5
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 5
235000010469 Glycine max Nutrition 0.000 description 5
241000282414 Homo sapiens Species 0.000 description 5
239000002253 acid Substances 0.000 description 5
150000007513 acids Chemical class 0.000 description 5
238000004166 bioassay Methods 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000004108 freeze drying Methods 0.000 description 5
238000000265 homogenisation Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
229940104230 thymidine Drugs 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
108020004511 Recombinant DNA Proteins 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
150000002170 ethers Chemical class 0.000 description 4
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
229940047122 interleukins Drugs 0.000 description 4
239000012528 membrane Substances 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
150000003904 phospholipids Chemical class 0.000 description 4
238000013207 serial dilution Methods 0.000 description 4
238000003860 storage Methods 0.000 description 4
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
239000004201 L-cysteine Substances 0.000 description 3
235000013878 L-cysteine Nutrition 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
235000021355 Stearic acid Nutrition 0.000 description 3
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
239000007900 aqueous suspension Substances 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000011109 contamination Methods 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
-1 glucolipids Chemical class 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
239000008117 stearic acid Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
238000009210 therapy by ultrasound Methods 0.000 description 3
239000010936 titanium Substances 0.000 description 3
229910052719 titanium Inorganic materials 0.000 description 3
238000000108 ultra-filtration Methods 0.000 description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
239000004322 Butylated hydroxytoluene Substances 0.000 description 2
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
241000282620 Hylobates sp. Species 0.000 description 2
208000029462 Immunodeficiency disease Diseases 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
235000021314 Palmitic acid Nutrition 0.000 description 2
229920005654 Sephadex Polymers 0.000 description 2
239000012507 Sephadex™ Substances 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
238000013019 agitation Methods 0.000 description 2
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
235000020661 alpha-linolenic acid Nutrition 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
239000012062 aqueous buffer Substances 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
229940095259 butylated hydroxytoluene Drugs 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000003729 cation exchange resin Substances 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
239000003480 eluent Substances 0.000 description 2
229940044627 gamma-interferon Drugs 0.000 description 2
150000008282 halocarbons Chemical class 0.000 description 2
238000009775 high-speed stirring Methods 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
229960004488 linolenic acid Drugs 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000000463 material Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
239000002245 particle Substances 0.000 description 2
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
239000000047 product Substances 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
238000011084 recovery Methods 0.000 description 2
239000000523 sample Substances 0.000 description 2
239000013049 sediment Substances 0.000 description 2
239000008347 soybean phospholipid Substances 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000007704 transition Effects 0.000 description 2
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108700031361 Brachyury Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010010099 Combined immunodeficiency Diseases 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
206010011831 Cytomegalovirus infection Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101100232904 Homo sapiens IL2 gene Proteins 0.000 description 1
101001010591 Homo sapiens Interleukin-20 Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
206010021450 Immunodeficiency congenital Diseases 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
102000003814 Interleukin-10 Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241000288906 Primates Species 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-AKLPVKDBSA-N Sulfur-35 Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
150000001449 anionic compounds Chemical class 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
150000001767 cationic compounds Chemical class 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
229930183167 cerebroside Natural products 0.000 description 1
150000001784 cerebrosides Chemical class 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
238000012258 culturing Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000012897 dilution medium Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000008344 egg yolk phospholipid Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
150000002321 glycerophosphoglycerophosphoglycerols Chemical class 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
230000028993 immune response Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
238000009776 industrial production Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940076144 interleukin-10 Drugs 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 1
229940044173 iodine-125 Drugs 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
239000002523 lectin Substances 0.000 description 1
235000020778 linoleic acid Nutrition 0.000 description 1
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical class 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
150000008103 phosphatidic acids Chemical class 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
239000002994 raw material Substances 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
208000002491 severe combined immunodeficiency Diseases 0.000 description 1
JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
150000003408 sphingolipids Chemical class 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
229940042585 tocopherol acetate Drugs 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Dispersion Chemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LU85839A 1984-04-09 1985-04-05 Perfectionnements a la therapie par l'interleukine LU85839A1 (fr)

Applications Claiming Priority (14)

Application Number	Priority Date	Filing Date	Title
GB8409125		1984-04-09
GB848409125A GB8409125D0 (en)	1984-04-09	1984-04-09	Interleukin therapy
GB8409128		1984-04-09
GB8409127		1984-04-09
GB848409128A GB8409128D0 (en)	1984-04-09	1984-04-09	Interleukin therapy
GB848409127A GB8409127D0 (en)	1984-04-09	1984-04-09	Interleukin therapy
GB848409126A GB8409126D0 (en)	1984-04-09	1984-04-09	Interleukin therapy
GB8409126		1984-04-09
GB8420381		1984-08-10
GB848420381A GB8420381D0 (en)	1984-08-10	1984-08-10	Interleukin therapy
GB848423700A GB8423700D0 (en)	1984-09-19	1984-09-19	Interleukin therapy
GB8423701		1984-09-19
GB848423701A GB8423701D0 (en)	1984-09-19	1984-09-19	Interleukin therapy
GB8423700		1984-09-19

Publications (1)

Publication Number	Publication Date
LU85839A1 true LU85839A1 (fr)	1985-12-16

Family

ID=27562708

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU85839A LU85839A1 (fr)	1984-04-09	1985-04-05	Perfectionnements a la therapie par l'interleukine

Country Status (13)

Country	Link
US (1)	US4863740A (de)
JP (1)	JPH0665650B2 (de)
AU (1)	AU4094685A (de)
CH (1)	CH668554A5 (de)
DE (1)	DE3512926A1 (de)
DK (1)	DK155085A (de)
FR (1)	FR2562421B1 (de)
GB (1)	GB2157172B (de)
IL (1)	IL74835A0 (de)
IT (1)	IT1199967B (de)
LU (1)	LU85839A1 (de)
NL (1)	NL8501010A (de)
SE (1)	SE8501709L (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5059421A (en) *	1985-07-26	1991-10-22	The Liposome Company, Inc.	Preparation of targeted liposome systems of a defined size distribution
EP0225130B1 (de) *	1985-11-22	1991-10-30	Takeda Chemical Industries, Ltd.	Liposomzusammensetzung
EP0274219A3 (de) *	1986-12-04	1988-08-03	Takeda Chemical Industries, Ltd.	Interleukin-2 enthaltende Liposan-Zusammensetzung und Methode zu ihrer Herstellung
FR2624741B1 (fr) *	1987-12-21	1991-06-28	Pasteur Institut	Compositions a base d'une combinaison de liposomes et de lymphokine presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire
EP0577146A3 (de) *	1988-05-16	1994-02-02	NeXstar Pharmaceuticals, Inc.	An Hormone gekoppelte Liposomen
US5258499A (en) *	1988-05-16	1993-11-02	Vestar, Inc.	Liposome targeting using receptor specific ligands
WO1989011270A1 (en) *	1988-05-16	1989-11-30	Sandoz Ag	Liposomes coupled to hormones
ATE147633T1 (de) *	1988-10-27	1997-02-15	Univ Minnesota	Immunhilfsmittel aus liposome enthaltend lymphokin il -2
US5234912A (en) *	1989-02-14	1993-08-10	Incyte Pharmaceuticals, Inc.	Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
WO1991000289A2 (en) *	1989-06-23	1991-01-10	The Liposome Company, Inc.	Targeted liposomes and methods for liposome-protein coupling
JPH0363298A (ja) *	1989-07-31	1991-03-19	Green Cross Corp:The	コロニー形成刺激因子・脂質複合体
US20020150539A1 (en)	1989-12-22	2002-10-17	Unger Evan C.	Ultrasound imaging and treatment
US5268454A (en) *	1991-02-08	1993-12-07	La Jolla Pharmaceutical Company	Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
DE4038075C1 (en) *	1990-11-29	1992-03-19	B. Braun Melsungen Ag, 3508 Melsungen, De	Encapsulating solid or liq. lipophilic agents - comprises mixing hydration medium with phospholipid increasing temp. to above soln. phase change temp. and adding remaining medium
US5205290A (en)	1991-04-05	1993-04-27	Unger Evan C	Low density microspheres and their use as contrast agents for computed tomography
US5817333A (en) *	1991-10-31	1998-10-06	Fujisawa Pharmaceutical Co., Ltd.	Liposome preparation containing a tricyclic compound
CA2127107C (en) *	1991-12-31	2007-06-19	Bruce L. A. Carter	Methods and compositions for reducing blood loss
US5229109A (en) *	1992-04-14	1993-07-20	Board Of Regents, The University Of Texas System	Low toxicity interleukin-2 analogues for use in immunotherapy
SI9300468A (en) *	1992-10-14	1994-06-30	Hoffmann La Roche	Injectable composition for the sustained release of biologically active compounds
US5449663A (en) *	1993-06-11	1995-09-12	Bicher; Haim I.	Antineoplastic compositions
US7083572B2 (en)	1993-11-30	2006-08-01	Bristol-Myers Squibb Medical Imaging, Inc.	Therapeutic delivery systems
US6521211B1 (en)	1995-06-07	2003-02-18	Bristol-Myers Squibb Medical Imaging, Inc.	Methods of imaging and treatment with targeted compositions
US6033645A (en) *	1996-06-19	2000-03-07	Unger; Evan C.	Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6406689B1 (en)	1995-10-03	2002-06-18	Frank W. Falkenberg	Compositions and methods for treatment of tumors and metastatic diseases
US7452551B1 (en)	2000-10-30	2008-11-18	Imarx Therapeutics, Inc.	Targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) *	1997-05-13	2002-07-09	Bristol-Myers Squibb Medical Imaging, Inc.	Acoustically active drug delivery systems
EP1003531B1 (de)	1997-05-20	2007-08-22	Ottawa Health Research Institute	Verfahren zur Herstellung von Nukleinsäurekonstrukten
DE69829995T2 (de) *	1997-12-01	2006-02-23	Fang, Fang, San Diego	Multivalente rekombinante antikörper zur behandlung von hrv infektionen
US20010003580A1 (en) *	1998-01-14	2001-06-14	Poh K. Hui	Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
AU756570B2 (en) *	1998-01-16	2003-01-16	Biomira Inc.	Lipomatrix preparation
DE69912441T2 (de)	1998-08-19	2004-08-19	Skyepharma Canada Inc., Verdun	Injizierbare wässerige propofoldispersionen
US20030035798A1 (en)	2000-08-16	2003-02-20	Fang Fang	Humanized antibodies
WO2001068828A2 (en)	2000-03-13	2001-09-20	Engene, Inc.	Compositions and methods for regulated protein expression in gut
AU2001249389A1 (en) *	2000-03-22	2001-10-03	The Children's Hospital Of Philadelphia	Modified blood clotting factors and methods of use
EP1578917A4 (de)	2001-07-19	2008-01-23	Perlan Therapeutics Inc	Multimere proteine und verfahren zu deren herstellung und verwendung
US20030044354A1 (en) *	2001-08-16	2003-03-06	Carpenter Alan P.	Gas microsphere liposome composites for ultrasound imaging and ultrasound stimulated drug release
TWI461436B (zh)	2005-11-25	2014-11-21	Kyowa Hakko Kirin Co Ltd	人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
EP1795540A1 (de)	2005-11-30	2007-06-13	Imaxio	Multipler Komplex aus Antigenen und einem Adjuvans
US20070248539A1 (en) *	2006-04-24	2007-10-25	Shantha West Inc.	AgRM2 antigen
EP2101813B1 (de)	2006-11-27	2014-04-02	Patrys Limited	Neues glykosyliertes zielpeptid in neoplastischen zellen
JP5748653B2 (ja)	2009-04-10	2015-07-15	協和発酵キリン株式会社	抗ｔｉｍ−３抗体を用いた血液腫瘍治療法
JP5694923B2 (ja)	2009-04-27	2015-04-01	協和発酵キリン株式会社	血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体
WO2011060233A1 (en)	2009-11-11	2011-05-19	The Trustees Of The University Of Pennsylvania	Anti-tem1 antibodies and uses thereof
US9783610B2 (en)	2012-04-27	2017-10-10	The Trustees Of The University Of Pennsylvania	Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
US9790269B2 (en)	2013-02-08	2017-10-17	Misfolding Diagnostics, Inc.	Transthyretin antibodies and uses thereof
EP3013945B1 (de)	2013-06-25	2020-05-27	Temple University Of The Commonwealth System Of Higher Education	Aus kortikalem knochen gewonnene stammzellen
BR112018070948A2 (pt)	2016-04-13	2019-01-29	Orimabs Ltd.	anticorpos anti-psma e utilização dos mesmos
EP4585226A1 (de)	2022-09-09	2025-07-16	Institute Of Science Tokyo	Therapeutikum für coronavirus-infektion

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5186117A (en) *	1975-01-27	1976-07-28	Tanabe Seiyaku Co	Johoseibiryushiseizainoseiho
GB1578776A (en) *	1976-06-10	1980-11-12	Univ Illinois	Hemoglobin liposome and method of making the same
US4235871A (en) *	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4377567A (en) *	1978-10-02	1983-03-22	The Procter & Gamble Company	Lipid membrane drug delivery
JPS55153713A (en) *	1979-05-02	1980-11-29	Kureha Chem Ind Co Ltd	Pharmaceutical preparation of ribosome containing active substance
JPS56127308A (en) *	1980-03-11	1981-10-06	Green Cross Corp:The	Blood-coagulation factor 8 pharmaceutical
DE3374837D1 (en) *	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
JPH0751511B2 (ja) *	1982-03-15	1995-06-05	味の素株式会社	インターロイキン２を含有してなる癌治療剤
AU564876B2 (en) *	1982-03-29	1987-08-27	Liposome Company, Inc., The	Stable plurilamellar vesicles
US4522803A (en) *	1983-02-04	1985-06-11	The Liposome Company, Inc.	Stable plurilamellar vesicles, their preparation and use
EP0109861A3 (de) *	1982-11-23	1986-05-14	Bio-Response Inc.	Verfahren zum Absondern von Zellen
WO1985000606A1 (fr) *	1983-07-19	1985-02-14	Takeda Chemical Industries, Ltd.	Il-2 humaine et son procede de preparation
US4464461A (en) *	1983-07-22	1984-08-07	Eastman Kodak Company	Development of light-sensitive quinone diazide compositions
US4764359A (en) *	1984-05-25	1988-08-16	Lemelson Jerome H	Drug compositions and their use in treating human or other mammalian patients
CA1260393A (en) *	1984-10-16	1989-09-26	Lajos Tarcsay	Liposomes of synthetic lipids

1985
- 1985-04-02 FR FR858505117A patent/FR2562421B1/fr not_active Expired
- 1985-04-02 CH CH1415/85A patent/CH668554A5/de not_active IP Right Cessation
- 1985-04-03 DK DK155085A patent/DK155085A/da not_active IP Right Cessation
- 1985-04-04 GB GB08508809A patent/GB2157172B/en not_active Expired
- 1985-04-04 NL NL8501010A patent/NL8501010A/nl not_active Application Discontinuation
- 1985-04-04 SE SE8501709A patent/SE8501709L/ not_active Application Discontinuation
- 1985-04-05 LU LU85839A patent/LU85839A1/fr unknown
- 1985-04-08 IL IL74835A patent/IL74835A0/xx unknown
- 1985-04-08 JP JP60075265A patent/JPH0665650B2/ja not_active Expired - Lifetime
- 1985-04-09 AU AU40946/85A patent/AU4094685A/en not_active Abandoned
- 1985-04-09 IT IT47939/85A patent/IT1199967B/it active
- 1985-04-11 DE DE19853512926 patent/DE3512926A1/de not_active Withdrawn
1988
- 1988-05-12 US US07/193,423 patent/US4863740A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
FR2562421A1 (fr)	1985-10-11
NL8501010A (nl)	1985-11-01
GB2157172A (en)	1985-10-23
IT1199967B (it)	1989-01-05
JPH0665650B2 (ja)	1994-08-24
IT8547939A1 (it)	1986-10-09
JPS60243022A (ja)	1985-12-03
CH668554A5 (de)	1989-01-13
GB8508809D0 (en)	1985-05-09
GB2157172B (en)	1988-12-29
IT8547939A0 (it)	1985-04-09
SE8501709L (sv)	1985-10-10
US4863740A (en)	1989-09-05
SE8501709D0 (sv)	1985-04-04
FR2562421B1 (fr)	1989-02-17
AU4094685A (en)	1985-10-17
IL74835A0 (en)	1985-07-31
DK155085D0 (da)	1985-04-03
DE3512926A1 (de)	1985-10-24
DK155085A (da)	1985-10-10

Publication	Publication Date	Title
LU85839A1 (fr)	1985-12-16	Perfectionnements a la therapie par l'interleukine
EP0004223B1 (de)	1981-09-09	Verfahren zur Herstellung von biologisch wirksame Mittel enthaltenden lipidischen Kapseln, nach diesem Verfahren hergestellte Produkte sowie ihre Anwendung
EP0161445B1 (de)	1988-09-21	Wasserlöslicher Arzneistoffkomplex sowie Verfahren zu dessen Herstellung
FI86371C (fi)	1992-08-25	Foerfarande foer framstaellning av farmaceutiska liposomkompositioner.
BE1001760A5 (fr)	1990-02-27	Supports de médicaments.
CA1323838C (en)	1993-11-02	Prostaglandin-lipid formulations
JP3074733B2 (ja)	2000-08-07	脂肪乳剤
WO1992019752A1 (fr)	1992-11-12	Vecteur de delivrance d'arn
KR102565469B1 (ko)	2023-08-16	비타민 c가 포집된 리포좀 및 이의 제조방법
JP2002503685A (ja)	2002-02-05	エリスロポイエチンのリポソーム分散物
EP0491921B1 (de)	1996-02-07	Verfahren zur herstellung eines durch einbau einer lipophilen wirksubstanz modifizierten lipoproteins
JP2001510786A (ja)	2001-08-07	脂質剤及びタンパク質を含む脂質粒子の医薬組成物の製造方法
FR2596651A1 (fr)	1987-10-09	Nouveaux liposomes a base de phosphatidylinositolmannosides, et compositions pharmaceutiques les contenant
CA1273575A (en)	1990-09-04	Pharmaceutical compositions consisting of acylated phospholipids
EP0165123A2 (de)	1985-12-18	Lipophile Muramylpeptid-Derivate mit einer makrophagen aktivierenden Wirkung, die sie enthaltenden Zusammensetzungen und Verfahren zu ihrer Herstellung
BE902089A (fr)	1985-10-02	Perfectionnements a la therapie par l'interleukine.
EP0277849A1 (de)	1988-08-10	Aufnahme von einem oder mehreren lipophilen, aktiven Bestandteilen in Lipoproteinen, hergestellte Lipoproteine und pharmazeutische Zusammensetzungen
JP2660341B2 (ja)	1997-10-08	リポソーム製剤およびその製造法
US20250367117A1 (en)	2025-12-04	Vitamin c-encapsulated liposome and preparation method therefor
JPH09501168A (ja)	1997-02-04	生物構造体、生体ポリマー及び／又はオリゴマーを充填した小胞の調製方法
JPH01290634A (ja)	1989-11-22	インターフェロン含有リポソーム製剤およびその製造法
JPH0482839A (ja)	1992-03-16	蛋白質類・脂質小体複合体
WO2022162131A1 (fr)	2022-08-04	Compositions liposomales orales
WO2003068189A1 (fr)	2003-08-21	Vesicules lipidiques, preparation et utilisations
WO1995001163A1 (fr)	1995-01-12	Nouvelles preparations pharmaceutiques a base de peptides pour la voie generale